Chemistry:CP-122,288

From HandWiki
Short description: Chemical compound
CP-122,288
CP-122,288 Structure.svg
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
Chemical and physical data
FormulaC16H23N3O2S
Molar mass321.44 g·mol−1
3D model (JSmol)

CP-122,288 is a drug which acts as a potent and selective agonist for the 5-HT1B, 5-HT1D and 5-HT1F serotonin receptor subtypes. It is a derivative of the migraine medication sumatriptan, but while CP-122,288 is 40,000 times more potent than sumatriptan as an inhibitor of neurogenic inflammation and plasma protein extravasation, it is only twice as potent as a constrictor of blood vessels. In human trials, CP-122,288 was not found to be effective as a treatment for migraine, but its selectivity for neurogenic anti-inflammatory action over vasoconstriction has made it useful for research into the underlying causes of migraine.[1][2][3][4][5]

See also

References

  1. "Conformationally restricted sumatriptan analogues, CP-122,288 and CP-122,638 exhibit enhanced potency against neurogenic inflammation in dura mater". Brain Research 626 (1–2): 303–5. October 1993. doi:10.1016/0006-8993(93)90591-a. PMID 8281439. 
  2. "The pre- and postjunctional activity of CP-122,288, a conformationally restricted analogue of sumatriptan". European Journal of Pharmacology 276 (3): 271–6. April 1995. doi:10.1016/0014-2999(95)00080-5. PMID 7601213. 
  3. "[3H]sumatriptan labels both 5-HT1D and 5-HT1F receptor binding sites in the guinea pig brain: an autoradiographic study". Naunyn-Schmiedeberg's Archives of Pharmacology 352 (3): 263–75. September 1995. doi:10.1007/bf00168556. PMID 8584041. 
  4. "The in vivo pharmacological profile of a 5-HT1 receptor agonist, CP-122,288, a selective inhibitor of neurogenic inflammation". British Journal of Pharmacology 116 (5): 2385–90. November 1995. doi:10.1111/j.1476-5381.1995.tb15084.x. PMID 8581273. 
  5. "No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo-controlled clinical trials". Annals of Neurology 47 (2): 238–41. February 2000. doi:10.1002/1531-8249(200002)47:2<238::AID-ANA15>3.0.CO;2-L. PMID 10665496.